Medicare Enrolled

Dr. Marcelo Boek, M.D.

Medical Oncology · McAllen, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1901 S 2ND ST, McAllen, TX 78503
9566875150
In practice since 2006 (19 years)
NPI: 1134166788 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Boek from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Boek? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Boek

Dr. Marcelo Boek is a medical oncology in McAllen, TX, with 19 years in practice. Based on federal Medicare data, Dr. Boek performed 24,186 Medicare services across 1,826 unique beneficiaries.

Between the years covered by Open Payments, Dr. Boek received a total of $6,133 from 40 pharmaceutical and/or device companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Boek is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 34% volume in TX$ $6,133 industry payments

Medicare Practice Summary

Medicare Utilization ↗
24,186
Medicare services
Top 34% in TX for medical oncology
1,826
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,273 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Contrast dye for imaging (iodine-based)11,858$0$3
Iron sucrose injection (Venofer)5,600$0$2
Epoetin alfa injection (Retacrit) for anemia976$6$28
Dexamethasone injection (steroid)962$0$1
Office visit, established patient (30-39 min)522$89$368
Complete blood count (CBC) with differential519$8$36
Injection, granisetron hydrochloride, 100 mcg430$0$24
Blood draw (venipuncture)427$8$20
Comprehensive metabolic blood panel410$10$64
Administration of chemotherapy into vein, 1 hour or less218$97$707
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less175$22$157
Lactate dehydrogenase (enzyme) level144$6$31
Red blood count automated, with additional calculations141$5$26
Iron level test137$6$27
Iron binding capacity test137$9$35
Ferritin level test (iron stores)136$13$60
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less126$47$313
Administration of chemotherapy into vein, each additional hour125$21$161
Injection, zoledronic acid, 1 mg122$6$431
Drug injection, under skin or into muscle113$10$96
Reticulated (young) platelet measurement100$35$143
CT scan of abdomen and pelvis with contrast94$170$1,067
Administration of additional new drug or substance into vein, 1 hour or less87$49$344
Injection of additional new drug or substance into vein82$12$108
Ct scan of chest with contrast77$51$821
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg66$353$1,722
Injection, diphenhydramine hcl, up to 50 mg65$1$7
Microscopic examination for white blood cells with manual cell count63$4$22
Complete blood count (CBC), automated63$6$34
Irrigation of implanted venous access drug delivery device59$16$114
New patient office visit, complex (60-74 min)58$146$709
PSA test (prostate cancer screening)41$18$94
Office visit, established patient, complex (40-54 min)22$131$496
Hospital follow-up visit, high complexity17$91$357
Nuclear medicine study from skull base to mid-thigh with ct scan14$1,108$4,802
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.2% high complexity
86.0% medium
12.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$6,133
Total received (2018-2024)
Avg $876/year across 7 years
Top 44% in TX for medical oncology
40
Companies
107
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,074 (99.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$59 (1.0%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$906
2023
$1,624
2022
$1,003
2021
$12
2020
$404
2019
$1,116
2018
$1,068

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$862
E.R. Squibb & Sons, L.L.C.
$744
Eisai Inc.
$458
Lilly USA, LLC
$420
Amgen Inc.
$396
Genentech USA, Inc.
$377
Merck Sharp & Dohme LLC
$366
Taiho Oncology, Inc.
$198
Merck Sharp & Dohme Corporation
$193
Rigel Pharmaceuticals, Inc.
$146
GlaxoSmithKline, LLC.
$143
Sumitomo Pharma America, Inc.
$141
Janssen Biotech, Inc.
$134
EISAI INC.
$111
Regeneron Healthcare Solutions, Inc.
$107
Exelixis Inc.
$104
Novartis Pharmaceuticals Corporation
$103
Jazz Pharmaceuticals Inc.
$102
Celgene Corporation
$101
Karyopharm Therapeutics Inc.
$99
Helsinn Therapeutics (U.S.), Inc.
$86
Sobi, Inc
$85
ADC Therapeutics America, Inc.
$82
Seagen Inc.
$72
Mirati Therapeutics, Inc.
$67
GENZYME CORPORATION
$63
Gilead Sciences, Inc.
$57
PFIZER INC.
$40
Bayer HealthCare Pharmaceuticals Inc.
$33
ARRAY BIOPHARMA INC
$31
Myovant Sciences Inc.
$29
Tempus AI, Inc
$24
Takeda Pharmaceuticals U.S.A., Inc.
$24
Medtronic, Inc.
$23
JAZZ PHARMACEUTICALS INC.
$23
Janssen Pharmaceuticals, Inc
$22
Blueprint Medicines Corporation
$19
Puma Biotechnology, Inc.
$18
BeiGene USA, Inc.
$17
Astellas Pharma US Inc
$12
Top 3 companies account for 33.6% of total payments
Associated products mentioned in payments ›
AYVAKIT · Avastin · BRUKINSA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · ENJAYMO · EVENITY · Erleada · GAZYVA · Halaven · IBRANCE · IMFINZI · INLYTA · KEYTRUDA · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LYNPARZA · Lenvima · Lonsurf · NERLYNX · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · OSTEOCOOL RF ABLATION SYSTEM · PIQRAY · Perjeta · Pomalyst · Prolia · REBLOZYL · RYBREVANT · SARCLISA · SCEMBLIX · Stivarga · TAGRISSO · TASIGNA · TIVDAK · TRUSELTIQ · Tavalisse · Tecentriq · Trodelvy · VERZENIO · VPRIV · VYXEOS · Vectibix · XALKORI · XPOVIO · Xtandi · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $25 per 100 Medicare services performed
Looking for a medical oncology in McAllen?
Compare medical oncologys in the McAllen area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
10
Per 100K population
1.1
County median income
$52,281
Nearest hospital
RIO GRANDE REGIONAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Boek is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Boek experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Boek performed 11,858 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Boek receive payments from pharmaceutical companies?
Yes. Dr. Boek received a total of $6,133 from 40 companies across 107 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Boek's costs compare to other medical oncologys in McAllen?
Dr. Boek's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Boek) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →